UBS Group
OBIO icon

UBS Group’s Orchestra BioMed OBIO Stock Holding History

UBS Group’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$214K Buy
50,310
+38,921
+342% +$166K ﹤0.01% 6601
2025
Q4 		$47.3K Buy
11,389
+7,574
+199% +$30.6K ﹤0.01% 7248
2025
Q3 		$9.46K Sell
3,815
-22,324
-85% -$61.6K ﹤0.01% 8599
2025
Q2 		$70.1K Buy
26,139
+8,869
+51% +$25.9K ﹤0.01% 7512
2025
Q1 		$73.9K Sell
17,270
-6,795
-28% -$33.8K ﹤0.01% 7286
2024
Q4 		$96.3K Buy
24,065
+12,583
+110% +$67.6K ﹤0.01% 6900
2024
Q3 		$59K Buy
11,482
+4,328
+60% +$28.3K ﹤0.01% 6710
2024
Q2 		$58.3K Sell
7,154
-7,572
-51% -$43.9K ﹤0.01% 6575
2024
Q1 		$77.6K Buy
14,726
+1,294
+10% +$8.77K ﹤0.01% 6325
2023
Q4 		$123K Buy
13,432
+5,938
+79% +$40.5K ﹤0.01% 6063
2023
Q3 		$65.3K Buy
7,494
+79
+1% +$531 ﹤0.01% 6117
2023
Q2 		$51.9K Buy
+7,415
New +$112K ﹤0.01% 6454
2022
Q4 		– Sell
-2,824
Closed -$28K – 11013
2022
Q3 		$28K Buy
2,824
+2,327
+468% +$23.1K ﹤0.01% 6957
2022
Q2 		$5K Buy
497
+440
+772% +$4.37K ﹤0.01% 8908
2022
Q1 		$1K Buy
+57
New +$563 ﹤0.01% 9898
2021
Q4 		– Sell
-537
Closed -$5K – 10562
2021
Q3 		$5K Sell
537
-590
-52% -$5.82K ﹤0.01% 8547
2021
Q2 		$12K Buy
1,127
+249
+28% +$2.58K ﹤0.01% 7892
2021
Q1 		$10K Buy
878
+851
+3,152% +$10.4K ﹤0.01% 7933
2020
Q4 		$0 Buy
+27
New +$308 ﹤0.01% 8630

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

UBS Group's OBIO Position: Q1 2026 in Review

UBS Group increased its Orchestra BioMed (OBIO) stake by 342% in Q1 2026, buying an estimated $166K and bringing the position to 50,310 shares worth $214K. The position accounts for ﹤0.01% of the portfolio, ranked #6601.

UBS Group first reported a position in OBIO in Q4 2020 and has held it in 19 quarters since. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • UBS Group held 50,310 shares of Orchestra BioMed worth $214K as of Q1 2026.
  • UBS Group bought 38,921 Orchestra BioMed shares in Q1 2026, an estimated $166K.
  • Orchestra BioMed made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6601 holding.
  • UBS Group first reported a position in Orchestra BioMed in Q4 2020 and has held it in 19 quarters since.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.